Mast cell phenotype in benign and Malignant tuMors of the prostate

Introduction
Prostatepathologyisacommonprobleminmen over50years.AccordingtotheWorldHealthOrganization(WHO),lifeexpectancywillsignificantlyincreaseinthenextdecades,andthereforeitisexpected thatthenumberofpatientswithprostatetumorprocesseswillincreasealso [1] .Prostatecarcinoma(PCa) andbenignprostatichyperplasia(BPH)arethemost common diseases affecting the prostate, and constitute over 90% of all prostate diseases. Although manytissuemarkerswithdiagnosticandtherapeutic impact have been analyzed in the last decades, the prognosisofprostatediseasesremainselusive.
Mastcells(MCs)arepresentinseveralorgans,including the lung, skin, heart, and digestive system. MultipleevidencesustainsMCsinnormalandespeciallyinmalignancyofvariousorgansashavingvariousphenotypes,mediatorscontentanddifferentresponsetovariousstimuli [2] [3] [4] [5] .MCsareinvestigated fortheirinvolvementinangiogenesis,tissueremodelingandstromaimmunomodulationofhumancancers,buttheroleofmastcellsremainscontroversial. MCscanexertpro-oranti-tumoreffectsdepending ontumortypeandtumormicroenvironment [6] .
The morphologic and functional complexity of MCs could explain the discrepancy between data fromdifferentstudiesshowingthepossibleinfluence ofMCsinprognosisandsurvivalofpatientswithvariousmalignancies [7] .Inthiscontext,prostatecancer isnotanexception.Severalstudieshaveattemptedto solvethisproblem [8] [9] [10] [11] [12] ,buttherearenocertified andconvincingdataabouttheactualroleofMCsas promotersorsuppressorsofcancerand/orbenignlesionsoftheprostate.
Basedonthepreviousstatedfactsandcontroversies, we aim to study MCs' role in benign and malignant lesions of the prostate, by a qualitative and quantitativeanalysisofMCs,regardingdistribution and immunophenotypes of MCs in normal, benign andmalignantconditionsoftheprostate.Ourstudy proposed to use three different antibodies to better characterize phenotype and mast cell distribution heterogeneitysuggestedbypreviousstudiesforprostatepathology. 
Material and methods
89biopsieswerecollectedfrompatientswithpros
Results
Distribution of mast cells in normal prostate
Fornormaltissuespecimens,MCswerefounddistributed in all three main histological zones of the prostate. Differences in their morphology were observeddependingontheirdifferentlocation.Often, these cells showed a more elongated shape, found nearthebasalmembraneofglandularepithelium.In addition,MCswerepresentintheaxisoftheglandular fold. MCs were predominantly located in the periglandular areas, close to blood vessels of prostatestroma.MCsoftheperiglandularareasshowed ahighdegreeofdegranulationcomparedwiththose frominter-glandularareas.ThedensityofMCspositivefortryptaseintheperiglandularstromawas20.4 ±1.3 compared with interglandular stroma, where thisdensitywas11.7±0.7.Chymase-positiveMCs havebeencharacterizedasmuchsmallerthantryptase-positiveMCsandaremostcommonlyspreadin theperiglandularstroma,usuallyarrangedingroups ornests.Mastcelldensity(MCD)ofchymase-positive cellsperareaismuchlowerthanfortryptase-positive MCs; thus in the inter-glandular areas the average was3.9±1.3andintheperiglandularareasitwas 10.2±1.2.Higherdensityofc-kitpositiveMCswas observed in the periglandular stroma (13.9 ±1.8) thanintheinter-glandularstroma(9.8±0.9).
TheresultsfoundfornormalprostatetissuesuggestedtheexistenceinnormalprostateofthreeMC typeshavingdistinctphenotypes.AparticularobservationwasthatMCshavethehighestdensityinside peri-glandularstromacomparedwithinter-glandular stroma.
The intra-glandular quantification of tryptase, chymaseandCD117inthenormalprostateshowed astatisticallysignificantcorrelation(p=0.030)betweentheexpressionoftryptaseandchymase.Thus, a unique tryptase+, chymase+, CD117-intraglandularphenotypewasobserved.
For the periglandular area, mast cell phenotype tryptase+,chymase-,CD117+wasquantified.
Distribution of mast cells in benign proliferative lesions
The distribution of tryptase positive MCs in the BPHdidnotdifferfromtheresultsobtainedfornormalprostatetissue.MCswerefoundalongtheblood vesselgroupedinsmallcellclusters.Peritumoralmast cellshapewasroundoroval,andforintratumoralareaselongatedandoftenlocatedintheglandularfold. MC density in intratumoral areas increased. C-kit (CD117)positiveMCshadaparticulardistribution. ThedistributionofMCswasnotuniform,mostoften formingclusters(groups)ofcellsorbeingdistributed incords.Thisdistributionwascharacteristicforboth peritumoralandintratumoralstromalareas (Fig.1) .
AhigherdensityofCD117-positiveMCsaccompanied inflammatory infiltrates from some BPH specimens.Distributionofchymase-positiveMCsdid not differ from results obtained in normal prostate. Tryptase-positive MCs are distributed uniformly insidetheinflammatoryzone.Thec-kitpositiveMCs haveapredilectionfortheperipheralzoneofinflammatoryinfiltrate.ThedensityofMCsinBPHwasin thenormalrange,maintainingahigherdistribution in peritumoral areas. MCD data, depending on the typeofthemarker,arerecordedinTableI.
The intratumoral and peritumoral ratios of three MC types were different; thus the intratumoral and peritumoralexpressionforeachmarkershowedastatisticallysignificantcorrelationfortryptase(p=0.001), CD117(p=0.008)andchymase(p=0.033).There arenosignificantstatisticalcorrelationsbetweentryptase-positive MCs and chymase-positive cells, tryptase and CD117, as well as chymase and CD117 in the intratumoral zones. This fact suggest the existence of aheterogeneousMCpopulation.QuantificationofMCs intheperitumoralarea,usingthreetypesofmarkers, showedasignificantcorrelationbetweentryptaseand CD117(p=0.011)andbetweenchymaseandCD117 (p=0.022).Theseresultshighlightthepresenceoftwo immunophenotypesofMCs:tryptase+CD117+chy-mase-andchymase+CD117+tryptase-.
Mast cells in malignant proliferative lesions
Tryptase-positive MC density decreased in the intratumoral versus peritumoral areas. Intratumor MCs were distributed among isolated tumor cells. We noted that in 13 cases (20.3%) intratu-
Fig. 1. ImmunohistochemicalstainingforCD117inbenignproliferativelesions.Localizationofc-kitpositiveMCs,formingcords (A) orcluster (B).Originalmagnification100×
A B (Fig. 3) . The total average of MCs for all three markers in normal stroma was higherthanintumorstromaofmalignantlesions.
Tryptase expression in malignant lesions was significantlycorrelatedwithintratumoralandperitumoral MCs (p = 0.001). The same correlation was demonstrated for CD117 (p = 0.001). For chymase a partial significant correlation was obtained(Kendall=0.024,Spearman=0.017).The peritumoral tryptase positive MCs were significantly correlated with both chymase (p = 0.001) and CD117 (p = 0.001), but not intratumoral correlationofchymasewithCD117wasobserved. Theseresultssuggestedthepresenceinsidethetumor areas of two distinct MCs phenotypes: chymase+/tryptase+/CD117-and chymase-/ tryptase+/CD117+. Peritumoral areas were characterized by statistically significant correlations between all three immunophenotypes,comparedtotheintratumoralphenotypeoftheMCs.Peritumorally,therewas demonstratedthepresenceofonemoreparticular phenotype:chymase+/tryptase+/CD117+.
TheprognosticimpactofMCphenotypewasdetermined by correlating the total number of MCs and Gleason score, based on the results described above in the malignant lesions. Relationships betweenGleasonscoreandstudiedmarkers(tryptase, chymase and CD117) were highly heterogeneous. Peritumoral tryptase-positive MCs were partially correlated with Gleason score (Kendall = 0.037, Spearman = 0.038, but not Pearson), as well as peritumoral chymase-expressing MCs (Kendall = =0.044,Spearman=0.033,norforPearson).
Intheintratumoralareastherewasnostatistically significant correlation for tryptase and chymase with Gleason score. A particular aspect was thesignificantpartialcorrelationbetweenCD117 expression in MCs and Gleason score, given that theothertwotypesofMCs(tryptaseandchymase) werenotcorrelatedwithGleasonscore.
Theabovedata,aswellasCD117expressionby tumor cells in some prostate tumors, suggest the involvementofc-kitpositiveMCsintheinitiation andmaintenanceofthemalignantprocess.
Discussion
Prostatecanceristhemostcommonmalecancer and the second leading cause of cancer death after Fig. 2.CD117+MCsinsertedbetweenendothelialcellsofonebloodvesselfromprostatecarcinoma(A,magnification  200×)andtryptase+MCstrappedbetweenepithelialtumorcellsfromprostatecarcinoma(B,magnification400×) A B
lungmalignancies.ChangesinthestromacaninitiatethedevelopmentofBPHandepithelial-stromal interactionsmayplayaroleinmalignantprogression [13] [14] [15] [16] [17] . Theroleofprostatestromalcellsislittlestudied, bothinnormalstromaandinmalignantandbenign pathologyoftheprostate.Activationofthestromal microenvironmentisbelievedtobeanimportantelementinthegrowthandprogressionofadenocarcinoma.Thefirststepinunderstandingthestromal-tumorinteractionistodefinetheroleofeachstromal cellatonemomentofthedevelopmentofbenignand malignantprostatelesions.Reactivestromaisamixtureoffibroblasts,endothelialcells,myofibroblasts, MCsandotherimmunecells.Themastcellisoneof themostcontroversialstromalcells,theirrolebeing proved to be complex and thus incompletely elucidatedatthismoment.Severalstudieshavesuggested thepotentialinvolvementofMCsinthepathogenesis ofvarioustumorsasmelanocyticskinlesions [18] or squamouscellcarcinomas [19] butothersshowedthe relationship between MCs and tumors due to their cytotoxicactionontumorcells [20, 21] ortheirabilitytodeliverproductswithananti-tumoreffect [22] .
Multiple conflicting results about accumulation of MCsintumorconditionshavebeenreported [23] .It isnotknownwhetherMCsaredesignedtostimulate orinhibittumorcells'spread [24] ,butacorrelation betweenMCsandsurvivalinvariouscancerswasobserved [25] . LittleattentionhasbeenpaidtotheroleofMCs in patients with malignant tumors of the prostate, MCsbeingmorestudiedregardingtheirinfluenceon angiogenesis than on tumor biology [26, 27] . The reportsarecontroversial,someshowinganincreasein thenumberofMCsinPCa [8, 10] ,whileothersstate thatthenumberofsuchcellsisnotchangedorisdecreased [11] .Thelackofinformationabouttherole ofmastcellsinbenignandmalignantprostatetransformations derives from incomplete immunophenotype characteristic of MCs not only in benign or malignantlesions,butalsoinnormalstroma.Thus, inourstudy,weusedthreemarkers-anti-mastcell tryptase,chymaseandCD117-whichallowacomplete characterization of MC immunophenotypes. C-kit,tyrosinekinasereceptor,ingeneral,hasbeen shown to be important for tumor growth and progressioninmanytypesofcancer [28] ,andmutation of c-kit has a central pathogenic role, for example, in gastrointestinal stromal tumors [29] . The present study demonstrated a high density of MCs in thestromaofnormalprostate.Ourresultssuggesteddifferentmastcellphenotypesinnormalprostate stroma,whichcouldexplainthedualroleofMCsin differenttumors.
Using heterogeneous immunophenotypes for normal, benign and malignant conditions. Attempts to highlightthelevelofMCsintheprostateorotherorgans have been made, but lacking differential immunophenotypeassessment.
A correlation between mast cell infiltration and prognosis has been described in various human tumors [30, 31] .Recently,inprostatecancer,MCswere identified as a new independent prognostic marker, andhavebeensuggestedasatherapyassociatedwith castration [32] . However, previous studies on prostatebiopsiesdemonstratedthatahighmastcelldensityisassociatedwithfavorabletumorcharacteristics andgoodprognosis [10] .Thedifferencesindatacan beexplainedbythefactthatprostatecancerisamultifocaldiseaseandeachtumorusuallyischaracterized byneoplasticfociwithmultipleheterogeneouscharacteristics.
Expression of c-kit in cases of BPH may suggest autocrine signaling for tumor cells. Recent reports describethealterationofpatternforc-kitandKL-ligandexpressioninBPHandPCa.ItseemsthatKL induces proliferation and maturation of MCs with releaseofproteases.ThiscanexplaintheaccumulationofMCsintumors,aphenomenonthatwasnot observedinnormalprostate [9] .Expressionofc-kit bytumorcellsissuggestedasacompetitionbetween tumorcellsandMCsforligandKL-ligand.Itissuggested that MCs could have an unexpected role in thecontrolofprostatehomeostasis,enteringintothe competitionwithprostatestemcells [33] .
The significant correlation between tryptase and chymase in peritumoral areas of malignant lesions suggestsanewmastcellphenotype,tryptase+chy-mase+CD117+,comparedtothemastcellphenotypeofbenignlesions,fromperitumoralareas:tryptase+ CD117+ chymase-. Chymase involvement in malignant transformation is supported by the existence of partial correlations with Gleason score and chymase-positiveMCslocatedperitumorally. Ourresultssuggesttheexistenceofaspecificmast cellphenotypicheterogeneityforprostatelesions.Recently,Manninkaet al.suggestedmastcellphenotypicheterogeneitydespitetheiroriginfromacommon precursor [34] . Numerous studies support the phenotypicheterogeneityofMCs,whichcouldbeused asdiagnosticmarkersandtargetedtherapy [35, 36] .
Our paper is the first report of the expression of mast cell heterogeneity in prostate cancer and its benignlesions.Thechangesofmastcellphenotype describedinthepresentpapersupportMCs'involvementinthepathogenesisofprostatecancerbiology, probably due to their differential and dual role in progressionfrombenigntomalignantlesions.Apart fromthecorrelationwithtumorgrade,furtherstudies will be necessary to demonstrate differential involvementofMCsindifferenthistopathologictypes ofprostatecancer.Bytheirphenotypicheterogeneity andhighdensityinbenignandmalignantlesionsof theprostate,MCscouldbeusedaspotentialtherapeutictargetsforadjuvanttherapies.
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